Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults

Journal of Infectious Diseases

Volumn 198, Issue 12, 2008, Pages 1776-1782

  Hammitt, Laura L ^a,b,e,f   Bulkow, Lisa ^a   Hennessy, Thomas W ^a   Zanis, Carolyn ^a   Snowball, Mary ^c   Williams, James L ^c   Bell, Beth P ^d   McMahon, Brian J ^a,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c Liver Disease and Hepatitis Program   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f NONE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSAGE SCHEDULE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS A VIRUS; HUMAN; IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; VACCINATION;

ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INDIANS, NORTH AMERICAN; MALE; TIME FACTORS;

EID: 56749153502     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/593335     Document Type: Article

References (22)

1. Advisory Committee on Immunization Practices, Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-23.
2. Bialek SR, Thoroughman DA, Hu D, et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 2004; 94:996-1001.
3. Bulkow LR, Wainwright RB, McMahon BJ, Middaugh JP, Jenkerson SA, Margolis HS. Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis 1993; 168:1017-20.
4. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996; 150:733-9.
5. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995; 171:676-9.
6. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63:1-7.
7. Chan C-Y, Lee S-D, Yu M-I, Wang Y-J, Chang F-Y, Lo K-J. Long-term follow-up of hepatitis A vaccination in children. Vaccine 1999; 17:369-72.
8. Fan P-C, Chang M-H, Lee P-I, Safary A, Lee C-Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998; 16:232-5.
9. Maiwald H, Jilg W, Bock HL, Loscher T, Sonnenburg Fv. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15:346-8.
10. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72:194-6.
11. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202-10.
12. Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005; 294:246-48.
13. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194-201.
14. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1-30.
15. State of Alaska Department of Health and Social Services. Annual reported cases of hepatitis in Alaska. Accessible at: http://www.epi.hss.state.ak.us/id/ hepatitis/cases.htm. Accessed 20 February 2008.
16. Bell BP, Negus SE, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007; 26:116-22.
17. Wang H, Chen X, Chen Z, et al. Field performance of VAQTA (inactivated, purified hepatitis a vaccine) in Chinese children in Jiangsu. Southeast Asian J Trop Med Public Health 2004; 35:949-53.
18. Roberton D, Marshall H, Nolan TM, et al. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children. Vaccine 2005; 23:5099-105.
19. Van Damme P, Van der Wielen M. Combining hepatitis A and B vaccination in children and adolescents. Vaccine 2001; 19:2407-12.
20. Cederna JB, Klinzman D, Stapleton JT. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalininactivated hepatitis A vaccine. Vaccine 1999; 18:892-8.
21. Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakok K. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J 2002; 21:727-30.
22. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362:1065-71.